NJBIZ Honors New Jersey's General Counsels Par's Martin Wilson Among Finalists
WOODCLIFF LAKE, N.J., April 1, 2013 /PRNewswire/ -- Martin L. Wilson, Chief Counsel, Compliance & Litigation, has been named a finalist in the Corporate Compliance Professional category in the 2013 NJBIZ General Counsel of the Year Awards program. The award program, produced by NJBIZ, New Jersey's premiere business news publication, is sponsored by Nicoll Davis & Spinella LLP, Real Estate Strategies, Update Discovery, Gibbons P.C., Archer & Greiner P.C., K&L Gates, Budd Larner, and Deloitte.
The General Counsel of the Year Awards program honors New Jersey's standout General Counsels, Chief Legal Officers and corporate compliance professionals for the critical role they play in making their companies successful. Finalists were selected in six categories: Public Company with revenues up to $1 Billion, Public Company with revenues of more than $1 Billion, Corporate Compliance Professional, Private Company with revenues up to $1 Billion, Private Company with revenues of more than $1 Billion, and Non-profit or Government Organization.
Finalists and winners were chosen by an independent panel of judges including: Mayor Gerald R. Drasheff, Christine Pellizzari, Christopher Klein, and Anthony Tinari. Honorees were selected using a scoring system based on: career successes, legal victories and achievements, professional services provided and community service.
The General Counsel of the Year Awards finalists will be recognized and the winners in each category will be announced during a breakfast awards ceremony on Thursday, June 6, 2013 at the Palace in Somerset Park in Somerset, NJ.
For more information about the NJBIZ General Counsel of the Year Awards program or to reserve seats to the event, please visit www.njbiz.com/events or contact Melissa Sullenberger at firstname.lastname@example.org or (732) 246-5737.
About Par Pharmaceutical Companies, Inc.
Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty pharmaceutical company that develops, manufactures and markets high barrier-to-entry generic drugs and niche, innovative proprietary pharmaceuticals through its wholly-owned subsidiary's two operating divisions, Par Pharmaceutical and Strativa Pharmaceuticals. For press release and other company information, visit www.parpharm.com.
SOURCE Par Pharmaceutical Companies, Inc.